Brokerages forecast that Phibro Animal Health Corp (NASDAQ:PAHC) will report $0.43 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Phibro Animal Health’s earnings, with the lowest EPS estimate coming in at $0.41 and the highest estimate coming in at $0.44. Phibro Animal Health reported earnings of $0.38 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 13.2%. The business is expected to issue its next earnings report on Monday, November 5th.
On average, analysts expect that Phibro Animal Health will report full year earnings of $1.80 per share for the current fiscal year, with EPS estimates ranging from $1.75 to $1.87. For the next year, analysts expect that the company will post earnings of $1.89 per share, with EPS estimates ranging from $1.88 to $1.90. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Phibro Animal Health.
Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Monday, August 27th. The company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.04. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The firm had revenue of $211.80 million for the quarter, compared to the consensus estimate of $209.27 million. During the same period in the previous year, the business earned $0.39 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year.
A number of analysts recently weighed in on the company. BidaskClub downgraded Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Zacks Investment Research downgraded Phibro Animal Health from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Barclays lifted their price target on Phibro Animal Health from $31.00 to $33.00 and gave the company an “underweight” rating in a research note on Thursday, July 5th. Credit Suisse Group lifted their price target on Phibro Animal Health from $39.00 to $42.00 and gave the company a “neutral” rating in a research note on Wednesday, May 9th. Finally, Morgan Stanley lifted their price target on Phibro Animal Health from $36.00 to $46.00 and gave the company an “underweight” rating in a research note on Wednesday, August 29th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $43.20.
In other Phibro Animal Health news, insider Jack Bendheim sold 30,000 shares of the business’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $50.20, for a total transaction of $1,506,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bfi Co., Llc sold 10,000 shares of the business’s stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $49.84, for a total value of $498,400.00. Following the sale, the insider now owns 60,000 shares in the company, valued at $2,990,400. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 410,940 shares of company stock worth $19,721,756. 51.88% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of PAHC. Royal Bank of Canada boosted its position in Phibro Animal Health by 2,104.6% during the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock worth $151,000 after purchasing an additional 3,641 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of Phibro Animal Health by 149.2% in the second quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after acquiring an additional 2,676 shares during the last quarter. Piedmont Investment Advisors LLC acquired a new position in shares of Phibro Animal Health in the second quarter worth $213,000. Highbridge Capital Management LLC acquired a new position in shares of Phibro Animal Health in the first quarter worth $214,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Phibro Animal Health in the second quarter worth $222,000. Institutional investors own 50.50% of the company’s stock.
Shares of Phibro Animal Health stock traded down $0.45 during trading on Monday, reaching $47.65. The company’s stock had a trading volume of 575 shares, compared to its average volume of 145,062. The company has a debt-to-equity ratio of 1.62, a current ratio of 2.90 and a quick ratio of 1.73. Phibro Animal Health has a 12-month low of $32.05 and a 12-month high of $54.62. The company has a market cap of $1.91 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 2.67 and a beta of 0.89.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 26th. Shareholders of record on Wednesday, September 5th will be given a dividend of $0.10 per share. The ex-dividend date of this dividend is Tuesday, September 4th. This represents a $0.40 dividend on an annualized basis and a yield of 0.84%. Phibro Animal Health’s payout ratio is 22.99%.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.
Featured Story: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.